CAS: 1672668-24-4; 3-(((1S,2S,3R)-2,3-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1H-Inden-4-yl)Oxy)-5-Fluorobenzonitrile

该化合物是一个小分子抑制剂,针对低氧水平细胞反应中各种基因的调控中涉及的分录系数2 alpha (HIF-2),该化合物的特点是它能够破坏HIF-2途径,该途径在某些癌症,特别是肾脏细胞癌中往往过于活跃;Belzutifan通过抑制这一途径,旨在减少肿瘤生长,改善患者结果;该物质通常通过口服方式施用,并研究其在治疗特定恶性病方面的功效;其化学结构包括各种功能组,这些功能组有助于其药理特性,包括溶性性和生物利用率;Belzutifan接受了临床试验,以评估其安全和有效性,并获得管制批准用于某些症状;与许多有针对性的疗法一样,其使用可能伴有特定的副作用,因此需要在治疗期间进行仔细监测.

结构式图片

欧盟法规

C&L通报

上下游产品

(s)-3-(((2,2-二氟-1-羟基-7-(甲基磺酰基)-2,3-二氢-1H-茚满-4-基)氧基)-5-氟苄腈 Pt2385 1672665-49-4

合成工艺路线路线简述

    [(1S,2S,3R)-4-(3-Cyano-5-Fluorophenoxy)-2,3-Difluoro-7-Methylsulfonylindan-1-Yl] Acetate置于lithium Hydroxide体系中,用 四氢呋喃 用作溶剂,化学反应 1.0H,反应生成3-[[(1S,2S,3R)-2,3-二氟-2,3-二氢-1-羟基-7-(甲基磺酰基)-1H-茚-4-基]氧基]-5-氟苄腈
    参考文献: Methods Of Reducing Inflammation Of The Digestive System With Inhibitors Of Hif-2-Alpha[fr] Procédés De Réduction De L'Inflammation Du Système Digestif à L'Aide D'Inhibiteurs De Hif-2-Alpha
    标题: Methods Of Reducing Inflammation Of The Digestive System With Inhibitors Of Hif-2-Alpha[fr] Procédés De Réduction De L'Inflammation Du Système Digestif à L'Aide D'Inhibiteurs De Hif-2-Alpha
    摘要:本公开提供了一种减少消化系统炎症的方法,适用于需要的对象,包括患有炎症性肠病的对象.同时还提供了用于这些方法的组合物.

    海关参考信息

    专利信息


    专利号:WO-2024010785-A1
    优先权日:2022-07-08
    标 题:Ketoreductase enzymes for the synthesis of 1,3-diol substituted indanes
    发明人:CAHN JACKSON KENAI BLENDER; CHEUNG-LEE WAI LING; CHUN STEPHANIE W; HIRAGA KAORI; KOSJEK BIRGIT; KNIGHT JOHN H; MAKAREWICZ AMANDA M; MCCANN SCOTT; MOORE JEFFREY C; VERMA DEEPTAK
    权利人:MERCK SHARP & DOHME LLC
    摘要:The present disclosure provides ketoreductase enzymes having improved enzymatic properties including the capability of reducing hydroxy indanones to provide diastereomerically pure 1,3-indane diols useful for the synthesis of belzutifan. Also provided are polynucleotides encoding the ketoreductase enzymes, and host cells capable of expressing the ketoreductase enzymes. A purification procedure for isolating the ketoreductase enzymes is also provided.

    专利号:US-2025215464-A1
    优先权日:2022-07-08
    标题 :Engineered enzyme for preparing a hydroxylated indanone intermediate useful in the synthesis of belzutifan
    发明人:CHEUNG-LEE WAI LING; DIROCCO DANIEL A; GIL AGNIESZKA; HIRAGA KAORI; KIM JUNGCHUL; KOLEV JOSHUA; KOSJEK BIRGIT; MALONEY KEVIN M; SALEHI MARZIJARANI NASTARAN; MCINTOSH JOHN; MCMULLEN JONATHAN P; MOORE JEFFREY C; MURPHY GRANT S; PAN WEILAN; VELASQUEZ VELEZ JUAN E; VERMA DEEPTAK; WINSTON MATTHEW S; XIAO LI; ZHANG VICTORIA
    权利人:MERCK SHARP & DOHME LLC
    摘要:The present disclosure provides enzymes derived from the fungi Fusarium oxysporum c8D (“FoPip4H enzymesâ€?) having improved properties as compared to a naturally occurring wild-type enzyme including the capability of hydroxylating certain substituted indanones to provide optically pure 3-hydroxyindanones. Also provided are polynucleotides encoding the FoPip4H enzymes, host cells capable of expressing the FoPip4H enzymes, and processes for using the FoPip4H enzymes to synthesize (R)-4-fluoro-3-hydroxy-7-(methylsulfonyl)-2, 3-dihydro-1H-inden-1-one, a useful intermediate in the synthesis of belzutifan.

    专利号:US-2022081407-A1
    优先权日:2020-09-11
    标题 :Methods of preparing substituted indanes
    发明人:STENGEL PETER J; XU RUI; SPENCER STACEY RENEE
    权利人:PELOTON THERAPEUTICS INC
    摘要:This application discloses methods for the synthesis of substituted indane analogs that modulate HIF-2α activity, as well as key intermediates produced thereby. The synthesis of 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile was exemplified.

    专利号:US-2021187130-A1
    优先权日:2019-12-19
    标题 :PET RADIOPHARMACEUTICALS FOR NON-INVASIVE EVALUATION OF HIF-2alpha
    发明人:BRUGAROLAS JAMES; SUN XIANKAI; DEBNATH SASHI
    权利人:UNIV TEXAS
    摘要:Provided herein are hypoxia inducible factor 2-alpha (HIF-2α)-specific radioactive tracers, methods of use thereof, and methods of synthesis thereof. Specifically, provided herein are HIF-2α-specific radioactive tracers comprising an HIF-2α-specific agent developed as a therapeutic inhibitor and a positron emitting radioactive label. Embodiments provide methods of detecting an HIF-2α-expressing tumor, detecting an HIF-2α inhibitor resistant tumor, evaluating a change in HIF-2α expression in response to an anti-cancer treatment, detecting acquisition of HIF-2α inhibitor resistance, evaluating efficacy of an HIF-2α depletion therapy, detecting or monitoring an ischemic area in a subject, or detecting and monitoring pulmonary hypertension in a subject. Also provided are methods of synthesizing an HIF-2α-specific radioactive tracer.

    专利号:EP-4551694-A1
    优先权日:2022-07-08
    标 题 :Ketoreductase enzymes for the synthesis of 1,3-diol substituted indanes

    专利号:EP-4551592-A1
    优先权日:2022-07-08
    标 题 :Engineered enzyme for preparing a hydroxylated indanone intermediate useful in the synthesis of belzutifan
    安徽凯泰莱铂科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.krl-tech.com
    企业联系电话:0512-66834346👤
    📞安徽凯泰莱铂科技有限公司 ⚠️参考联系方式
    联系人:郑朝晖
    电话:0512-66834346
    手机:17751128648

    邮箱:13916109676@163.com
    通信地址: 合肥市高新区孔雀台路习友路口国家健康大数据产业园C2-01栋
    邮编: 230041
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:合肥市高新区孔雀台路习友路口国家健康大数据产业园C2-01栋
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Deeks ED. Belzutifan: First Approval. Drugs. 2021 Nov;81(16):1921-1927. doi: 10.1007/s40265-021-01606-x. MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425.
    3: Visweswaran V, Pavithran K. Belzutifan: A Narrative Drug Review. Curr Drug Res Rev. 2022;14(2):88-95. doi: 10.2174/2589977514666220401094724. 27(5):802-805. doi: 10.1038/s41591-021-01324-7. Epub 2021 Apr 22. Erratum in: Nat Med. 2021 Oct;27(10):1849.
    5: Belzutifan. Am J Health Syst Pharm. 2021 Dec 9;78(24):2185-2187. doi: 10.1093/ajhp/zxab366. 28(22):4843-4848. doi: 10.1158/1078-0432.CCR-22-1054.

    合成参考文献


    摘要:Kleemann A., Kutscher B., Reichert D., Bossart M., Pharmaceutical Substances, Thieme [Online], Stuttgart, (2025).
    摘要:Caron, S.; Lee, J.; Liu, Y.; Nguyen, T. N.; Piper, J. L.; Vicini, A. C., Science of Synthesis: Modern Strategies in Organofluorine Chemistry, (2025) 2.
    摘要:Caron, S.; Lee, J.; Liu, Y.; Nguyen, T. N.; Piper, J. L.; Vicini, A. C., Science of Synthesis: Modern Strategies in Organofluorine Chemistry, (2025) 2.
    摘要:Caron, S.; Lee, J.; Liu, Y.; Nguyen, T. N.; Piper, J. L.; Vicini, A. C., Science of Synthesis: Modern Strategies in Organofluorine Chemistry, (2025) 2.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知